LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.Statistical...
Inventiva stock sinks 20% after serious adverse event in NASH trial
Revenues of ‚¬17.5 million for the full year of 2023, compared to ‚¬12.2 million for 2022Cash and cash equivalents at ‚¬26.9 million, short-term deposits at ‚¬ 0.01 million2, and long-term deposit at ‚¬9.0...
Daix (France), Long Island City (New York, United States), January 24, 2024 “ Inventiva (Euronext Paris and Nasdaq: IVA) (the Company), a clinical-stage biopharmaceutical company focused on...
Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH.This second tranche carries an interest rate of...
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva. With this milestone payment Inventiva expects...
The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety dataThe safety assessment was based on the review of safety data from...
Cash and cash equivalents at ‚¬43.8 million, short-term deposits at ‚¬0.03 million2, and long-term deposit at ‚¬5.0 million3 as of September 30, 2023, compared to ‚¬86.7 million, ‚¬1.0 million and ‚¬0.7...
The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.Two additional scientific abstracts from the NATIVE Phase IIb clinical...
Cash and cash equivalents at ‚¬31.2 million, short-term deposits at ‚¬0.05 million1, and long-term deposit at ‚¬9.3 million2, as of June 30, 2023, compared to ‚¬86.7 million, ‚¬1.0 million and ‚¬0.7 million...